Why Patients Switch GLP-1 Medications for Better Results
Understanding Wegovy Constipation When Switching Medications
Wegovy constipation represents one of the most commonly reported gastrointestinal side effects when patients switch from other GLP-1 receptor agonists like Mounjaro or consider starting semaglutide treatment. The mechanism behind constipation involves semaglutide's action on GLP-1 receptors in the digestive tract, which can slow gastric emptying and intestinal motility. Patients switching to Wegovy often experience constipation during the initial dose escalation phase, typically within the first 4-8 weeks of treatment. Understanding that Wegovy constipation is usually mild and transient helps patients make informed decisions about switching medications.
When switching from tirzepatide (Mounjaro) to semaglutide (Wegovy), patients may notice different patterns of gastrointestinal side effects, including constipation frequency and severity. Clinical data suggests that whilst both medications can cause constipation, individual tolerance varies significantly between patients. The EverydayMeds clinical team provides comprehensive support for patients experiencing Wegovy constipation during their medication switch, offering practical management strategies alongside ongoing prescription monitoring. This personalised approach ensures patients can successfully transition between GLP-1 medications whilst maintaining their weight management progress.
Switch & Save: Wegovy Pricing and Bundle Options
Switching to Wegovy can offer significant cost savings compared to other GLP-1 medications, with starter doses beginning at £79.99 for the 0.25mg pen. Our comprehensive pricing structure includes the Intro Duo bundle (0.25mg & 0.5mg) for £169.99, providing the first 8 weeks of treatment at exceptional value. New customers benefit from the FIRST40 discount code applied at checkout, whilst returning patients use DOSE25 to access these competitive prices. The Progress Trio bundle (0.5mg, 1mg & 1.7mg) costs £369.99, covering weeks 5-16 of the dose escalation schedule with convenient single-order delivery.
For patients requiring maintenance therapy, our Consistency bundles provide excellent value with the 2.4mg two-pen option at £419.99. The Ultimate Stability Trio offers three months of maintenance supply with 2.4mg pens for £649.99, ensuring uninterrupted treatment whilst managing Wegovy constipation through established routines. All pricing includes our comprehensive clinical support, next-day cold-chain delivery, and ongoing monitoring by our GPhC #9012878 registered pharmacy team. These transparent prices eliminate hidden costs and provide clear financial planning for patients switching their weight management medication.
Clinical Evidence for Wegovy Constipation Management
Clinical trials demonstrate that Wegovy constipation typically occurs in 20-24% of patients, with most cases classified as mild to moderate in severity. The STEP trial programme, particularly findings published by Wilding et al. in NEJM 2021, showed that gastrointestinal side effects including constipation generally decreased in frequency and intensity after the initial dose escalation period. Most patients experiencing Wegovy constipation found symptoms manageable with dietary modifications and adequate hydration.
Long-term safety data from the STEP trials indicates that constipation rarely leads to treatment discontinuation when properly managed with clinical support. The MHRA's continued monitoring through the Black Triangle system ensures ongoing safety surveillance for all side effects, including Wegovy constipation patterns. Our clinical team utilises this evidence base to provide patients with realistic expectations and effective management strategies during their medication switch.
How Wegovy Works in Your Digestive System
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of natural incretin hormones produced in your intestines. The medication works by binding to GLP-1 receptors throughout your digestive tract, slowing gastric emptying and promoting feelings of satiety after smaller meals. This mechanism naturally reduces appetite and food cravings by affecting brain appetite centres in the hypothalamus. However, the same gastric slowing effect that promotes weight loss can also contribute to Wegovy constipation in some patients. The once-weekly injection provides consistent hormone levels, helping maintain steady appetite suppression alongside a reduced-calorie diet and increased physical activity. Understanding this mechanism helps patients anticipate and manage potential side effects like constipation during their treatment journey.
Streamlined Ordering Process for Medication Switches
Switching to Wegovy through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, specifically designed to evaluate patients transitioning from other GLP-1 medications. Our prescribers review your medical history, current medication regimen, and any side effects like constipation you've experienced with previous treatments. Standard prescriber review takes 3 working days, with express 24-hour review available for urgent medication switches. Once approved, your Wegovy prescription ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication efficacy. Our pharmacy team coordinates with your previous prescription provider to ensure seamless transition timing, minimising any treatment gaps that could affect your weight management progress.
Storage and Practical Considerations for Wegovy
Wegovy requires refrigeration at 2-8°C before first use, offering a practical advantage with 6 weeks of room temperature stability once removed from the fridge. The FlexTouch pen system provides user-friendly injection administration, with clear dose markings and reliable medication delivery. Proper storage helps maintain semaglutide stability and reduces the risk of injection site reactions that could compound digestive side effects like constipation. The mandatory dose escalation schedule (0.25mg, 0.5mg, 1mg, 1.7mg, then 2.4mg maintenance) allows your digestive system to gradually adjust to the medication's effects. Following the prescribed escalation timeline helps minimise Wegovy constipation whilst building sustainable weight loss habits. Each pen contains four weeks of medication, requiring monthly prescription refills through our streamlined reorder system.
Managing Wegovy Constipation During Your Medication Switch
Patients switching to Wegovy benefit from proactive constipation management strategies implemented from their first injection. The EverydayMeds clinical team provides detailed guidance on dietary fiber intake, hydration requirements, and lifestyle modifications that can minimise digestive disruption during medication transitions. Unlike switching between completely different drug classes, moving from Mounjaro to Wegovy involves transitioning between GLP-1 receptor agonists with similar but distinct side effect profiles.
Our pharmacy's unique position stocking both Mounjaro and Wegovy enables seamless prescription management without transferring between different suppliers. This continuity proves particularly valuable for patients experiencing Wegovy constipation, as our clinical team maintains comprehensive records of your side effect history and management strategies. The ability to adjust dosing schedules or provide additional clinical support during your switch ensures optimal outcomes whilst maintaining cost-effective treatment access.
Start Your Wegovy Switch Today
Ready to switch to Wegovy whilst managing constipation concerns and saving money on your weight management medication? Our clinical assessment takes just 3 minutes, with new customers using code FIRST40 and returning patients applying DOSE25 at checkout for competitive pricing. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your prescription-only medicine assessment with our experienced clinical team. We provide comprehensive support throughout your medication switch, from initial dose conversion guidance to ongoing side effect management including Wegovy constipation strategies. Our GPhC #9012878 registered pharmacy ensures safe, legal, and effective treatment alongside your reduced-calorie diet and increased physical activity programme. Take control of your weight management journey with expert clinical support and transparent pricing designed for your long-term success.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
